Vomiting News and Research RSS Feed - Vomiting News and Research

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.
Norovirus vaccines: an interview with Dr Benjamin Lopman, Centers for Disease Control and Prevention, USA

Norovirus vaccines: an interview with Dr Benjamin Lopman, Centers for Disease Control and Prevention, USA

Noroviruses are a group of viruses. They're the leading cause of gastroenteritis, which causes diarrhea and vomiting. They affect the whole age range from young children to the elderly, and, in the US, they cause about 20 million cases annually. [More]
FDA approves Targiniq ER to treat severe pain

FDA approves Targiniq ER to treat severe pain

Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. [More]
Wake Forest Baptist shares tips to help avoid heat-related illnesses

Wake Forest Baptist shares tips to help avoid heat-related illnesses

Working out when it's hot isn't such a hot idea. Just ask Bret Nicks, M.D., associate professor of emergency medicine at Wake Forest Baptist Medical Center. [More]
Researchers use safer method to stimulate ovulation in women undergoing IVF treatment

Researchers use safer method to stimulate ovulation in women undergoing IVF treatment

Researchers have successfully used a new and potentially safer method to stimulate ovulation in women undergoing IVF treatment. [More]
FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

Astellas today announced that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive candidiasis, a life-threatening, invasive fungal infection. [More]
Once-a-day pill for patients experiencing opioid-induced constipation

Once-a-day pill for patients experiencing opioid-induced constipation

Opioids - strong morphine-based painkillers - are widely prescribed to patients experiencing chronic severe pain. While these drugs are very effective for treating and managing pain, they have one particularly bothersome side effect: constipation. [More]
Acupuncture can affect severity of hot flashes for women in natural menopause

Acupuncture can affect severity of hot flashes for women in natural menopause

In the 2,500+ years that have passed since acupuncture was first used by the ancient Chinese, it has been used to treat a number of physical, mental and emotional conditions including nausea and vomiting, stroke rehabilitation, headaches, menstrual cramps, asthma, carpal tunnel, fibromyalgia and osteoarthritis, to name just a few. [More]
New research opens up potential new therapeutic targets for hard-to-treat food allergy

New research opens up potential new therapeutic targets for hard-to-treat food allergy

New research in Nature Genetics identifies a novel genetic and molecular pathway in the esophagus that causes eosinophillic esophagitis (EoE), opening up potential new therapeutic strategies for an enigmatic and hard-to-treat food allergy. [More]
Kaleo announces U.S. availability of EVZIO for emergency treatment of opioid overdose

Kaleo announces U.S. availability of EVZIO for emergency treatment of opioid overdose

Kaleo, a privately-held pharmaceutical company headquartered in Richmond, Virginia, today announced the United States (U.S.) commercial availability of EVZIO for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. [More]
Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Astellas today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in immunocompromised patients. [More]
Samples from Chobani yogurt contain most virulent form of fungus

Samples from Chobani yogurt contain most virulent form of fungus

Samples isolated from Chobani yogurt that was voluntarily recalled in September 2013 have been found to contain the most virulent form of a fungus called Mucor circinelloides, which is associated with infections in immune-compromised people. [More]
FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). [More]
Forecast report on Global Ovarian Cancer market

Forecast report on Global Ovarian Cancer market

Research and Markets has announced the addition of the "Global Ovarian Cancer Market 2014-2018" report to their offering. [More]
Simple and hygienic measures can prevent campylobacter infections

Simple and hygienic measures can prevent campylobacter infections

In Switzerland, between 7000 and 8000 persons fall ill with a campylobacter infection annually. This makes it the most frequent bacterial disease transmitted through food. [More]
Multicenter trial aims to find safety, effectiveness of probiotics in infants with stomach flu

Multicenter trial aims to find safety, effectiveness of probiotics in infants with stomach flu

Consumers worldwide spend billions of dollars each year on probiotic foods and supplements. But studies evaluating probiotics - microorganisms believed to aid digestive health - have been limited. [More]
Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency's accelerated approval program. [More]
LINX Reflux Management System safe for patients suffering from GERD, shows new data

LINX Reflux Management System safe for patients suffering from GERD, shows new data

Torax Medical today announced the release of new data from two leading U.S. medical centers that further establishes the LINX Reflux Management System as a safe and effective procedure for patients suffering from gastroesophageal reflux disease (GERD). [More]
Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years. [More]
Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug. [More]
New estimates highlight the importance of developing norovirus vaccines

New estimates highlight the importance of developing norovirus vaccines

Noroviruses are a leading cause of acute gastroenteritis (diarrhoea and vomiting) across all age groups, responsible for almost a fifth (18%) of all cases worldwide. New estimates, published in The Lancet Infectious Diseases, highlight the importance of developing norovirus vaccines, say the authors. [More]